טוען...
An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
BACKGROUND: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an acceler...
שמור ב:
| הוצא לאור ב: | Clin Transl Allergy |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4736162/ https://ncbi.nlm.nih.gov/pubmed/26839682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0093-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|